• KinATLAS
  • TranscriptoNET
  • PhosphoNET
  • OncoNET
  • KinaseNET
  • DrugKiNET
  • DrugProNET
  • KiNET-AM
  • Kinetica Online

Updated November 2019

Home | Kinexus | Contact | Credits

Nomenclature

Short Name:
DYRK1A
Full Name:
Dual-specificity tyrosine-phosphorylation regulated kinase 1A
Alias:
  • DYR1A
  • DYRK
  • EC 2.7.12.1
  • EC 2.7.12.2
  • MNB
  • MNBH

Classification

Type:
Protein-serine/threonine kinase
Group:
CMGC
Family:
DYRK
SubFamily:
Dyrk1
 
 

Specific Links

BioCarta Entry: shh pathway
Entrez-Gene Entry: 1859
Entrez-Protein Entry: NP_569120
GeneCards Entry: MNBH
KinBASE Entry: DYRK1A
OMIM Entry: 600855
Pfam Entry: Q13627
PhosphoNET Entry: Q13627
Phosphosite Plus Entry: 1004
Protein Data Bank Entry: 2VX3
ScanSite Entry: Q13627
Source Entry: DYRK1A
UCSD-Nature Entry: A000796
UniProt Entry: Q13627
Kinexus Products: DYRK1A
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Y321 phosphosite-specific antibody AB-PK597
DYRKSubtide - DYRK1A protein kinase substrate peptide - Powder PE-01BHD95
Dual specificity tyrosine-phosphorylation-regulated kinase 1A (I318-S324, human) pY321 phosphopeptide - Powder PE-04AET99
Dual specificity tyrosine-phosphorylation-regulated kinase 1A (Q316-P330, human) pY319+pY321+pS324+pY327 phosphopeptide - Powder PE-04ATA50
Dual specificity tyrosine-phosphorylation-regulated kinase 1A (I318-S324, human) pY321 phosphopeptide - Powder PE-04BBR00

General Links

ClustalW2
GPS-Cuckoo
Human Protein Atlas
Kinase.com
Kinase Research
Kinasource
Kinomer
Netphorest
NetworKIN
Phosida
PhosphoElm
Protein Blast
ScanSite
String

Structure

Mol. Mass (Da):
85,584
# Amino Acids:
763
# mRNA Isoforms:
5
mRNA Isoforms:
85,584 Da (763 AA; Q13627); 84,556 Da (754 AA; Q13627-2); 66,099 Da (584 AA; Q13627-5); 61,770 Da (540 AA; Q13627-4); 60,330 Da (529 AA; Q13627-3)
4D Structure:
Interacts RAD54L2/ARIP4 By similarity. Interacts with RANBP9. Interacts with WDR68
1D Structure:
Retrieve Gene Sequence
Retrieve Full Protein Sequence
Retrieve Catalytic Domain Sequence
 
3D Image (rendered using PV Viewer):

PDB ID
2VX3

Subfamily Alignment
subfamily domain
 
Domain Distribution:
Start End Domain
159 479 Pkinase
 

Kinexus Products

Click on entries below for direct links to relevant products from Kinexus for this protein kinase.
hiddentext
○ Dual specificity tyrosine-phosphorylation-regulated kinase 1A Y321 phosphosite-specific antibody AB-PK597
○ DYRKSubtide - DYRK1A protein kinase substrate peptide - Powder PE-01BHD95
○ Dual specificity tyrosine-phosphorylation-regulated kinase 1A (I318-S324, human) pY321 phosphopeptide - Powder PE-04AET99
○ Dual specificity tyrosine-phosphorylation-regulated kinase 1A (Q316-P330, human) pY319+pY321+pS324+pY327 phosphopeptide - Powder PE-04ATA50
○ Dual specificity tyrosine-phosphorylation-regulated kinase 1A (I318-S324, human) pY321 phosphopeptide - Powder PE-04BBR00
 

Post-translation Modifications

For detailed information on phosphorylation of this kinase go to PhosphoNET
Acetylated:
K105.
Serine phosphorylated:

S14, S22, S127, S324, S529+, S538, S555, S706, S748, S758, S762.
Tyrosine phosphorylated:

Y111, Y112, Y136, Y145, Y147, Y159, Y219, Y319, Y321+, Y705.
Ubiquitinated:
K453.
 

Distribution

Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:
% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:
  • adipose
    100

    1542

    45

    2490

  • adrenal
    5

    84

    25

    85

  • bladder
    12

    184

    3

    277

  • brain
    28

    433

    129

    539

  • breast
    45

    699

    36

    641

  • cervix
    10

    153

    118

    213

  • colon
    30

    470

    55

    580

  • heart
    42

    650

    53

    918

  • intestine
    34

    530

    24

    548

  • kidney
    8

    121

    140

    137

  • liver
    6

    85

    36

    106

  • lung
    38

    585

    309

    634

  • lymphnode
    9

    144

    36

    195

  • ovary
    10

    157

    20

    171

  • pancreas
    7

    101

    28

    104

  • pituitary
    9

    132

    23

    157

  • prostate
    7

    115

    379

    133

  • salivarygland
    6

    96

    18

    76

  • skeletalmuscle"
    16

    253

    136

    346

  • skin
    35

    540

    162

    667

  • spinalcord
    11

    165

    24

    182

  • spleen
    13

    205

    30

    306

  • stomach
    4

    63

    30

    90

  • testis
    11

    162

    20

    158

  • thymus
    18

    270

    27

    400

  • thyroid
    52

    802

    72

    909

  • tonsil
    8

    117

    39

    147

  • trachea
    7

    113

    18

    110

  • uterus
    12

    183

    16

    190

  • reticulocytes"
    13

    200

    42

    139

  • t-lymphocytes
    47

    728

    54

    721

  • b-lymphocytes
    83

    1276

    51

    2140

  • neutrophils
    14

    216

    86

    326

  • macrophages
    51

    782

    93

    725

  • sperm
    21

    328

    66

    573

 

Evolution

Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
  • tableheader
    100

    100

    100
  • tableheader
    0

    0

    100
  • tableheader
    99.6

    99.8

    100
  • tableheader
    -

    -

    100
  • tableheader
    -

    -

    98
  • tableheader
    85.1

    85.5

    99.5
  • tableheader
    -

    -

    -
  • tableheader
    99.2

    99.4

    99
  • tableheader
    99.6

    99.7

    100
  • tableheader
    -

    -

    -
  • tableheader
    94.4

    95.2

    -
  • tableheader
    26.7

    39.9

    96
  • tableheader
    91.4

    94.2

    93.5
  • tableheader
    78.7

    84.2

    83
  • tableheader
    -

    -

    -
  • tableheader
    47.7

    60.2

    79
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
 

Binding Proteins

Examples of known interacting proteins
hiddentext
No. Name – UniProt ID
1 DCAF7 - P61962
2 GLI1 - P08151
3 PHYHIP - Q92561
4 YWHAE - P62258
5 CREB1 - P16220
6 SFRS16 - Q8N2M8
7 YWHAG - P61981
 

Regulation

Activation:
Phosphorylation at Tyr-321 increases phosphotransferase activity. Phosphorylation at Ser-529 increases phosphotransferase activity and association with 14-3-3-beta.
Inhibition:
Inhibited by RANBP9.
Synthesis:
NA
Degradation:
NA
 

Known Upstream Kinases

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.
Based on in vitro and/or in vivo phosphorylation data

Kinase Short Name UniProt ID (Human) Phosphosite Location Phosphosite Sequence Effect of Phosphorylation
DYRK1A Q13627 Y219 KHDTEMKYYIVHLKR
DYRK1A Q13627 Y321 LGQRIYQYIQSRFYR +
DYRK1A Q13627 S529 SNSGRARSDPTHQHR +
 

Known Downstream Substrates

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.
Based on in vitro and/or in vivo phosphorylation data

Substrate Short Name UniProt ID (Human) Phosphosite Location Phosphosite Sequence Effect of Phosphorylation
Amphiphysin P49418 S293 PAPARPRSPSQTRKG
Amphiphysin P49418 S295 PARPRSPSQTRKGPP
Amphiphysin P49418 T310 VPPLPKVTPTKELQQ
Amphiphysin P49418 T312 PLPKVTPTKELQQEN
Caspase 9 P55211 T125 PEVLRPETPRPVDIG
Cyclin N (CCNL2) Q96S94 S330 LDGTSGFSPAPKLVE
Cyclin N (CCNL2) Q96S94 S338 PAPKLVESPKEGKGS
Cyclin N (CCNL2) Q96S94 S369 AKKAKADSPVNGLPK
DYN1 Q05193 S795 VPPARPGSRGPAPGP
DYN1 Q05193 S857 ASPSRPESPRPPFDL
DYRK1A Q13627 S529 SNSGRARSDPTHQHR +
DYRK1A Q13627 Y219 KHDTEMKYYIVHLKR
DYRK1A Q13627 Y321 LGQRIYQYIQSRFYR +
eIF2B-e Q13144 S544 EPDSRGGSPQMDDIK
FOXO1A Q12778 S329 STISGRLSPIMTEQD -
GYS1 P13807 S641 YRYPRPASVPPSPSL -
GYS2 P54840 S641 FKYPRPSSVPPSPSG -
H3.1 P68431 T45 PHRYRPGTVALREIR
SF3B1 O75533 T273 ATPGRGDTPGHATPG
SF3B1 O75533 T434 PARKLTATPTPLGGM
SNCA P37840 S87 KTVEGAGSIAAATGF
Spry2 O43597 T75 KPAPRPSTQHKHERL
SRSF1 (SF2, ASF) Q07955 S226 NSRSRSYSPRRSRGS
SRSF1 (SF2, ASF) Q07955 S233 SPRRSRGSPRYSPRH
SRSF1 (SF2, ASF) Q07955 S237 SRGSPRYSPRHSRSR
STAT3 P40763 S727 NTIDLPMSPRTLDSL -
Tau iso5 (Tau-C) P10636-5 T212 TPGSRSRTPSLPTPP
Tau iso8 P10636-8 S199 GDRSGYSSPGSPGTP
Tau iso8 P10636-8 S202 SGYSSPGSPGTPGSR
Tau iso8 P10636-8 S396 GAEIVYKSPVVSGDT
Tau iso8 P10636-8 S404 PVVSGDTSPRHLSNV
Tau iso8 P10636-8 S422 GSIDMVDSPQLATLA
Tau iso8 P10636-8 T181 KTPPAPKTPPSSGEP
Tau iso8 P10636-8 T205 SSPGSPGTPGSRSRT
Tau iso8 P10636-8 T217 SRTPSLPTPPTREPK
Tau iso8 P10636-8 T231 KKVAVVRTPPKSPSS
 

Protein Kinase Specificity

Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites

Kinections GIF
Matrix Type:
Experimentally derived from alignment of 33 known protein substrate phosphosites.
Domain #:
1
 

Inhibitors

For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's
Based on in vitro and/or in vivo phosphorylation data
Compound Name KD, Ki or IC50 (nM) PubChem ID ChEMBL ID PubMed ID
A 443654 IC50 < 2 nM 10172943 379300
A674563 Kd = 2.1 nM 11314340 379218 22037378
Staurosporine Kd = 4 nM 5279 22037378
TTT-3002 IC50 < 6 nM
TG003 IC50 = 12 nM 1893668 408982 21450467
CHEMBL1474834 Kd = 13 nM 44223970 1474834 21450467
CHEMBL1551169 IC50 = 17 nM 46916176 1551169 21450467
Lestaurtinib Kd = 20 nM 126565 22037378
R547 Kd = 23 nM 6918852 22037378
CHEMBL1704879 IC50 = 26 nM 46916172 1704879 21450467
CHEMBL1436585 Kd = 27 nM 46916178 1436585 21450467
NCGC00010037 IC50 = 27 nM 3232621 21450467
CHEMBL1552755 IC50 = 30 nM 44223955 1552755 21450467
CHEMBL1591577 IC50 = 31 nM 44223973 1591577 21450467
CHEMBL1396654 IC50 = 35 nM 44223953 1396654 21450467
CHEMBL1515144 IC50 = 38 nM 44968186 1515144 21450467
JAK3 Inhibitor VI IC50 > 50 nM 16760524 22037377
K-252a; Nocardiopsis sp. IC50 > 50 nM 3813 281948 22037377
SB218078 IC50 > 50 nM 447446 289422 22037377
CHEMBL1396483 IC50 = 51 nM 44223971 1396483 21450467
CHEMBL1476499 IC50 = 57 nM 44223974 1476499 21450467
7-hydroxystaurosporine IC50 > 60 nM 72271 1236539
Staurosporine aglycone IC50 < 60 nM 3035817 281948
CHEMBL1705549 IC50 = 70 nM 46916170 1705549 21450467
CHEMBL1357975 IC50 = 74 nM 44223965 1357975 21450467
CHEMBL1354134 IC50 = 76 nM 46916179 1354134 21450467
Alvocidib Kd = 77 nM 9910986 428690 22037378
Gö6976 IC50 < 80 nM 3501 302449
Ro-31-8220 IC50 < 80 nM 5083 6291
CHEMBL1435542 Kd = 82 nM 44223952 1435542 21450467
CHEMBL1725513 IC50 = 84 nM 46916177 1725513 21450467
NCGC00010428 IC50 = 98 nM 3233012 21450467
Amgen TBK 1 inhibitor (Compound II) IC50 = 100 nM
BML-275 IC50 = 100 nM 11524144 478629
Harmine IC50 < 100 nM 5280953 269538
N-Benzoylstaurosporine Kd = 100 nM 56603681 608533 19654408
STO609 IC50 = 100 nM 51371511
SureCN3470757 IC50 = 100 nM 11588244 375236
2-dimethylamino-4;5;6;7-tetrabromo-1H-benzimidazole IC50 = 120 nM 5326976 376505 15566294
AT7519 Kd = 120 nM 11338033 22037378
CHEMBL566900 IC50 = 126 nM 44223977 566900 21450467
CHEMBL1734733 IC50 = 135 nM 46916182 1734733 21450467
ACN-S001855 IC50 > 150 nM 10377751 22037377
Cdk1/2 Inhibitor III IC50 > 150 nM 5330812 261720 22037377
PKR Inhibitor IC50 > 150 nM 6490494 235641 22037377
Enzastaurin Kd = 160 nM 176167 300138 22037378
KW2449 Kd = 180 nM 11427553 1908397 22037378
SB202190 IC50 < 200 nM 5353940 278041
Sunitinib Kd = 200 nM 5329102 535 19654408
PKCb Inhibitor IC50 > 250 nM 6419755 366266 22037377
Ruboxistaurin Kd = 250 nM 153999 91829 22037378
SU14813 Kd = 260 nM 10138259 1721885 22037378
BX517 IC50 > 300 nM 11161844 228654
AC1NS7CD Kd = 340 nM 5329665 295136 22037378
Purvalanol B IC50 < 400 nM 448991 23254
CHEMBL590109 IC50 = 440 nM 46224684 590109 19926477
AS601245 IC50 = 500 nM 11422035 191384 22037377
Bisindolylmaleimide I IC50 = 500 nM 2396 7463 22037377
Gö6976 IC50 = 500 nM 3501 302449 22037377
SU11652 IC50 = 500 nM 24906267 13485 22037377
Tpl2 Kinase Inhibitor IC50 = 500 nM 9549300 22037377
Cot-Tpl2 Inhibitor Compound 38 (Abbott) IC50 < 600 nM
Cot-Tpl2 Inhibitor Compound 41 (Abbott) IC50 < 600 nM
Curcumin IC50 < 600 nM 5281767 116438
GSK-3 Inhibitor IX IC50 < 600 nM 5287844 409450
Harmaline IC50 < 600 nM 5280951 340807
Purvalanol A IC50 < 600 nM 456214 23327
SGX523 Kd = 780 nM 24779724 1236107 22037378
1;9-Pyrazoloanthrone IC50 < 800 nM 8515 7064
KT5720 IC50 < 800 nM 3844 608532
LDN193189 IC50 < 800 nM 25195294 513147
PF-3644022 IC50 < 800 nM
NU6102 IC50 = 900 nM 4566 18077363
Ruxolitinib Kd = 910 nM 25126798 1789941 22037378
Afatinib Kd = 970 nM 10184653 1173655 22037378
4;5;6;7-tetrabromobenzotriazole IC50 = 1 µM 1694 18077363
Aloisine A IC50 > 1 µM 5326843 75680 22037377
BI-D1870 IC50 = 1 µM 25023738 573107
BX795 IC50 = 1 µM 10077147 577784
GSK650394A IC50 = 1 µM 25022668 558642
GW5074 (Raf1 Kinase Inhibitor I) IC50 < 1 µM 5924208
Harmane IC50 = 1 µM 5281404 12014
IPA-3 IC50 = 1 µM 521106 472940
IRAK-1-4 Inhibitor I IC50 = 1 µM 11983295 379787
IRAK-4 kinase inhibitor a IC50 = 1 µM
Kinome_714 IC50 > 1 µM 46886323 20346655
PD0332991 IC50 = 1 µM 5330286 189963
Quercetagetin IC50 < 1 µM 5281680 413552
R406 IC50 = 1 µM 11984591
SB216763 IC50 < 1 µM 176158
Sodium salicylate (Aspirin) IC50 = 1 µM 16760658 447868
SU6656 IC50 = 1 µM 5353978 605003
SureCN10063060 Ki > 1 µM 52936621 21391610
Syk Inhibitor IV IC50 = 1 µM 10200390
Wyeth PDK1 Inhibitor Compound 1 IC50 = 1 µM
WZ3146 Kd > 1 µM 44607360 20033049
WZ4002 Kd > 1 µM 44607530 20033049
GSK1838705A Kd = 1.2 µM 25182616 464552 22037378
Canertinib Kd = 1.5 µM 156414 31965 22037378
BS181 IC50 = 2 µM 49867928 19638587
EGCG (Epigallocatechin Gallate) IC50 < 2 µM 65064 297453
Momelotinib IC50 > 2 µM 25062766 19295546
SB415286 IC50 = 2 µM 4210951 322970
PP242 Kd = 2.3 µM 25243800 22037378
NVP-TAE684 Kd = 2.9 µM 16038120 509032 22037378
BIX02188 IC50 > 3 µM 23507698 18834865
Harmalol IC50 > 3 µM 5353656 311932
IRAK-4 kinase inhibitor b IC50 > 3 µM
CHEMBL248757 Ki = 3.401 µM 44444843 248757 17935989
SureCN4875304 IC50 > 3.5 µM 46871765 20472445
BCP9000822 IC50 < 4 µM 5278396 222102
Roscovitine IC50 < 4 µM 160355 14762
Syk Inhibitor III IC50 < 4 µM 672296 596380
Kenpaullone IC50 > 4.5 µM 3820 296586
 

Disease Linkage

General Disease Association:

Cancer, cognitive impairment
Specific Diseases (Non-cancerous):

Down syndrome; Mental retardation, autosomal dominant 7 (MRD7); Mental retardation, autosomal dominant 10
Comments:
Down Syndrome is a rare chromosome condition leading to cognitive impairment, distinct facial characteristics, and other health defects. Down Syndrome may have a relation to Alzheimer's disease as well. The phenotype of Mental retardation, autosomal dominant 7 (MRD7) disorder includes microcephaly, severe cognitive impairment (lacking speech), anxious autistic behaviour, and distinct facial characteristics. Kinase phosphotransferase activity of DYRK1A can be abrogated with the K188R mutation, or it can be mildly impaired with a Y321F mutation (which still maintains autophosphorylation of tyrosine residues).
 
Specific Cancer Types:
Megakaryocytic tumour, Epithelial and Lymphoid tumours
Comments:
Megakaryocytic tumours (derived from bone marrow cells responsible for producing red blood cells) can be induced with DYRK1A.
 
Gene Expression in Cancers:

The COSMIC website notes an up-regulated expression score for DYRK1A in diverse human cancers of 408, which is 0.9-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 348 for this protein kinase in human cancers was 5.8-fold of the average score of 60 for the human protein kinases.
Mutagenesis Experiments:

Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:

Percent mutation rates per 100 amino acids length in human cancers: 0.08 % in 25183 diverse cancer specimens. This rate is very similar (+ 7% higher) to the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:

Highest percent mutation rates per 100 amino acids length in human cancers: 0.41 % in 1093 large intestine cancers tested; 0.31 % in 589 stomach cancers tested; 0.3 % in 602 endometrium cancers tested; 0.13 % in 1753 lung cancers tested; 0.09 % in 1466 breast cancers tested.
Frequency of Mutated Sites:

None > 4 in 20,466 cancer specimens
Comments:
Only 3 deletions, 2 insertions, and no complex mutations are noted on the COSMIC website.
 
COSMIC Entry:
DYRK1A
OMIM Entry:
600855
  • Home
  • Top of Page
Copyright 2019 Kinexus BioInformatics Corporation